RxDoctor Payments Data

Stephen Pray

Psychiatric/Mental Health · Chandler, AZNPI 1114199759

Payments from drug & device makers

$3,851in general payments, 2019–2025

Across 65 payments — averaging $59.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$1K
  • Johnson & Johnson$838
  • Teva Pharmaceuticals USA, Inc.$536
  • Otsuka America Pharmaceutical, Inc.$312
  • E.r. Squibb & Sons, L.L.C.$269
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$186
  • plus $382 from 3 others

What the payments were for

  • Food & beverage$3,80299%
  • Education$491%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,851 in reported general payments places this provider in the 90th percentile of 1,230 psychiatric/mental health providers in Arizona.

See all psychiatric/mental health providers in Arizona

Medicare billing

Part B allowed, 2024
$10,625
Medicare patients
30
Services billed
124

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate122$395,019
Invega TrinzaPaliperidone Palmitate37$371,306
VraylarCariprazine Hcl50$74,821
Abilify MaintenaAripiprazole20$56,091
LybalviOlanzapine/Samidorphan Malate12$19,252
Aripiprazole161$15,128
Lurasidone Hcl34$14,622
Clozapine109$9,077
Duloxetine Hcl271$6,897
Quetiapine Fumarate166$5,811
Divalproex Sodium ErDivalproex Sodium109$4,734
Ziprasidone Hcl54$4,568
Bupropion XlBupropion Hcl177$4,560
Gabapentin178$3,880
Desvenlafaxine Succinate ErDesvenlafaxine Succinate57$3,067

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Invega Trinza$838$766,325159 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$312$56,09120 claims
Alkermes, Inc.Lybalvi$1,329$19,25212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,230 psychiatric/mental health providers in Arizona.

Other psychiatric/mental health in Chandler

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →